Initiating NTD programs targeting schistosomiasis and soil-transmitted helminthiasis in two provinces of the Democratic Republic of the Congo: Establishment of baseline prevalence for mass drug administration

Kaboré, Achille; Ibikounlé, Moudachirou; Tougoue, Jean Jacques; Mupoyi, Sylvain; Ndombe, Martin; Shannon, Scott; Ottesen, Eric A.; Mukunda, Faustin; Awaca, Naomi

doi:10.1016/j.actatropica.2016.11.023

Cited by 17 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Praziquantel (PZQ), a drug co-developed by Bayer AG and Merck KGaA in the 1970s, has been implemented in many national programs as an integral component of control and elimination strategies and is the drug of choice for the treatment of schistosomiasis (Olveda et al, 2016;Bergquist et al, 2017;Gower et al, 2017;Kabore et al, 2017;Kimani et al, 2018). Although PZQ is considered non-toxic and highly effective against adult schistosomes, it is unable to kill developing schistosomes and the individual remains susceptible to subsequent infections.…”

Section: Introductionmentioning

confidence: 99%

Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment

Melkus

Siddiqui

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

For decades, mass drug treatment with praziquantel (PZQ) has been utilized to treat schistosomiasis, yet reinfection and the risk of drug resistance are among the various factors precluding successful elimination of schistosomiasis. Tractable models that replicate "real world" field conditions are crucial to effectively evaluate putative schistosomiasis vaccines. Herein, we describe the cellular immune responses and cytokine expression profiles under field conditions that include prior infection with schistosomes followed by treatment with PZQ. Baboons were exposed to Schistosoma mansoni cercariae through trickle infection over 5 weeks, allowed for chronic disease to develop, and then treated with PZQ. Peripheral blood mononuclear cells (PBMCs) were monitored for cellular immune response(s) at each disease stage and PZQ therapy. After initial infection and during chronic disease, there was an increase in non-classical monocytes, NK and NKT cells while the CD4:CD8 T cell ratio inverted from a 2:1 to 1:2.5. The cytokine expressions of PBMCs after trickle infections were polarized more toward a Th2 response with a gradual increase in Th1 cytokine expression at chronic disease stage. Following PZQ treatment, with the exception of an increase in B cells, immune cell populations reverted back toward naïve levels; however, expression of almost all Th1, Th2, and Th17 cytokines was significantly increased. This preliminary study is the first to follow the cellular immune response and cytokine expression profiles in a non-human primate model simulating field conditions of schistosomiasis and PZQ therapy, providing a promising reference in predicting the immune response to future vaccines for schistosomiasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment

Melkus

Siddiqui

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Across all use-cases is an option to integrate and leverage the resources of other public health programs. For instance, many STH programs are integrated with schistosomiasis control efforts due to co-endemicity [ 8 , 26 ], with the Kato-Katz method also able to detect infection by Schistosoma mansoni and S . japonicum .…”

Section: Introductionmentioning

confidence: 99%

Diagnostic tools for soil-transmitted helminths control and elimination programs: A pathway for diagnostic product development

et al. 2018

View full text Add to dashboard Cite

“…Thus different findings from studies aiming at finding new alternative drugs, which can serve in the control of schistosomiasis, showed convincing antischistosomal activity of antimalarial including amodiaquine, mefloquine, primaquine, and artemisinin derivatives both in vitro and in vivo [ 11 – 18 ]. Despite the fact that the Ministry of Health has adopted a national plan to control neglected tropical diseases (NTDs), including schistosomiasis, based on mass drugs distributions in schools, whose implementation is progressive in the country since 2012 [ 19 , 20 ], contrarily from Kinshasa province, in Kongo central province, western part of DRC, the prevalence of schistosomiasis keeps increasing [ 3 ]. Nevertheless, the current situation about Schistosoma resistance to PZQ remains unknown.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Artesunate-Amodiaquine on Schistosoma mansoni Infection among Children Infected by Plasmodium in Rural Area of Lemfu, Kongo Central, Democratic Republic of the Congo

Mbanzulu

Zanga

Mukendi

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Background Malaria and schistosomiasis remain life-threatening public health problems in sub-Saharan Africa. The infection pattern related to age indicates that preschool and school-age children are at the highest risk of malaria and schistosomiasis. Both parasitic infections, separately or combined, may have negative impacts on the haemoglobin concentration levels. The existing data revealed that artemisinin derivatives commonly used to cure malaria present also in antischistosomal activities. The current study investigated the impact of Artesunate-Amodiaquine (AS-AQ) on schistosomiasis when administered to treat malaria in rural area of Lemfu, DRC. Methodology A prospective longitudinal study including 171 coinfected children screened for anaemia, Schistosoma mansoni, and Plasmodium falciparum infections. The egg reduction rate and haemoglobin concentration were assessed four weeks after the treatment with AS-AQ, of all coinfected children of this series. Results One hundred and twenty-five (74.4%) out of 168 coinfected children treated and present during the assessment were found stool negative for S. mansoni eggs. Out of 43 (25.6%) children who remained positives, 37 (22%) showed a partial reduction of eggs amount, and no reduction was noted in 3.6% of coinfected. The mean of haemoglobin concentration and the prevalence of anaemia were, respectively, 10.74±1.5g/dl , 11.2±1.3g/dl, and 64.8%, 51.8%, respectively, before and after treatment, p<0.001. Conclusion The AS-AQ commonly used against Plasmodium allowed curing S. mansoni in coinfected children and increasing the Hb level. For the future, the randomized and multicentric clinical trials are needed for a better understanding of the effectiveness of AS-AQ against Schistosoma spp. The trial registration number was 3487183.

show abstract

Initiating NTD programs targeting schistosomiasis and soil-transmitted helminthiasis in two provinces of the Democratic Republic of the Congo: Establishment of baseline prevalence for mass drug administration

Cited by 17 publications

References 13 publications

Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment

Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment

Diagnostic tools for soil-transmitted helminths control and elimination programs: A pathway for diagnostic product development

The Impact of Artesunate-Amodiaquine on Schistosoma mansoni Infection among Children Infected by Plasmodium in Rural Area of Lemfu, Kongo Central, Democratic Republic of the Congo

Contact Info

Product

Resources

About